<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196234</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2009-0677</org_study_id>
    <nct_id>NCT01196234</nct_id>
  </id_info>
  <brief_title>Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer</brief_title>
  <acronym>PRIDE</acronym>
  <official_title>Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for
      2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor
      receptor (EGFR) mutations.

      Expanded acronym : [P]aclitaxel/Ca[r]boplatin (PC) followed by Gef[i]tinib in A[d]vanc[e]d
      Non-small Cell Lung Cancer (NSCLC): Randomized phase II study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy
      followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While
      previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered
      the schedule of administration in hopes to gain synergy between agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>average 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>average 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>average 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel/Carboplatin/Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel/Carboplatin/Gefitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel/Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Carboplatin/Gefitinib</intervention_name>
    <description>paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15</description>
    <arm_group_label>Paclitaxel/Carboplatin/Gefitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Carboplatin</intervention_name>
    <description>paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)</description>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 18 years of age

          -  Histologically documented non-small cell lung cancer with metastasis (Stage IV) or
             locally advanced (Stage IIIB) with malignant effusion.

          -  At least 1 measurable lesion as defined by RECIST1.0. All target lesions must have a
             unidirectional diameter of at least 1cm. Baseline measurements must be compared within
             4 weeks prior to enrollment.

          -  ECOG PS 0-2

          -  At least 1 week since the last radiotherapy. Patients must have recovered from all
             acute toxicities from radiotherapy.

          -  Patients must have adequate hematologic, renal and liver function as defined by Hb &gt;
             9g/dL, neutrophils &gt; 1000/mm3, platelets &gt; 50,000/mm3, creatinine &lt; 2mg/dL, and AST
             (SGOT) and/or ALT (SGPT) &lt; 5 x UNL (upper normal limit).

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other study procedures.

          -  Written and voluntary informed consent understood, signed and dated.

        Exclusion Criteria:

          -  Patients with tumor harboring EGFR mutation.

          -  Prior systemic therapy for NSCLC

          -  Non-smoking patients with adenocarcinoma. But if those patients show wild type EGFR,
             they are eligible to this study.

          -  Symptomatic brain metastasis. Brain metastases stable &lt; 2 weeks before dosing or
             requiring concurrent steroid treatment or with clinical symptoms.

          -  Major surgery within 3 weeks prior to study enrollment.

          -  Previous (less than 3 years ago) or current malignancies at sites other than
             curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of
             the skin.

          -  Severe medical illness or active infection that would impair the ability to receive
             gefitinib.

          -  Pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-We Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sang-We Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

